Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 13/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.42 |
| ▸ | ARG1 | P05089 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7602936 | 0.86 | CCR5 (0.43) | CCR5NTRK1ARG1 | |
| SCHEMBL7938506 | 0.83 | CCR5 (0.44) | CCR5HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL7496849 | 0.83 | CCR5 (0.44) | CCR5HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL7604524 | 0.83 | CCR5 (0.39) | CCR5NTRK1ARG1HTR2AHTR2C | |
| SCHEMBL7603221 | 0.83 | NTRK1 (0.41) | CCR5NTRK1ARG1HTR2AHTR2C | |
| SCHEMBL7549348 | 0.79 | CCR5 (0.57) | CCR5HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL7931936 | 0.79 | CCR5 (0.57) | CCR5HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL7498060 | 0.79 | CCR5 (0.57) | CCR5HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL7931848 | 0.79 | CCR5 (0.57) | CCR5HTR2AHTR2CHTR2BRIPK1 | |
| SCHEMBL7552882 | 0.78 | CCR5 (0.41) | CCR5HTR2AHTR2CHTR2BRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | HALE JEFFREY J (US) | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CXCR1 | CCR5 1/4885NTRK1 2502/4885ARG1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.